Safety and efficacy of empagliflozin in heart failure among patients with a history of valvular heart disease: Insights from EMPEROR-Pooled
We present the first large analysis of SGLT2i (empagliflozin) use in HF patients by history of VHD. Although VHD history was associated with worse outcomes in HF patients, empagliflozin demonstrated consistent safety, efficacy, and patient-reported outcomes across all categories of VHD history.
Authors
- Ekene Nwajei
- Tomasz Gąsior (ORCID: https://orcid.org/0000-0001-5088-4164)
- Egon Pfarr (ORCID: https://orcid.org/0000-0002-7799-1733)
- Subodh Verma (ORCID: https://orcid.org/0000-0002-4018-8533)
- Nitish K. Dhingra
- Raj Kumar Verma (ORCID: https://orcid.org/0000-0003-2240-974X)
Institutions
- St. Michael's Hospital (CA)
- Boehringer Ingelheim (Germany) (DE)
Publication Details
- Journal
- JTCVS Open
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1016/j.xjon.2025.03.018
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eli Lilly and Company
- Boehringer Ingelheim